BioSpace News Archive

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) a clinical stage biopharmaceutical company focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, announced today that management will participate in two virtual investor conferences in January.

AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and oncologic diseases, today announced that the first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with Diabetic Macular Edema (DME).

NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines study leveraging company’s COVID-19 equipped transportation network across dozens of sites nationwide

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that Dr. James A. Hayward, president and CEO, will participate in a fireside chat at the virtual H.C. Wainwright BIOCONNECT 2021 Conference to be held January 11-14, 2021. The fireside chat will be hosted by Yi Chen, Managing Director, H.C. Wainwright Equity Research, and Applied DNA co

OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced the 510(k) approval, and limited U.S. launch of its first sterile-packed implants for the Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”). The PNP|FEMUR system, now available in 4 countries, was designed for use in pediatric patients to address femoral shaft fractures, subtrochanteric femur fract

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 1

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time. A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myo

Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center